Cargando…

Time to Surgery Does Not Affect Overall or Disease-Free Survival of Patients with Primary Resectable PDAC

(1) Background: Delay in therapy for pancreatic ductal adenocarcinoma (PDAC) may contribute to a worse outcome. The aim of this study was to investigate the prognostic value of time from diagnosis to surgery in patients undergoing upfront surgery for primarily resectable pancreatic carcinoma. (2) Me...

Descripción completa

Detalles Bibliográficos
Autores principales: Jacobsen, Anne, Hobbs, Mirianna, Merkel, Susanne, Mittelstädt, Anke, Czubayko, Franziska, Krautz, Christian, Weber, Georg F., Grützmann, Robert, Brunner, Maximilian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9369379/
https://www.ncbi.nlm.nih.gov/pubmed/35956049
http://dx.doi.org/10.3390/jcm11154433
_version_ 1784766438584614912
author Jacobsen, Anne
Hobbs, Mirianna
Merkel, Susanne
Mittelstädt, Anke
Czubayko, Franziska
Krautz, Christian
Weber, Georg F.
Grützmann, Robert
Brunner, Maximilian
author_facet Jacobsen, Anne
Hobbs, Mirianna
Merkel, Susanne
Mittelstädt, Anke
Czubayko, Franziska
Krautz, Christian
Weber, Georg F.
Grützmann, Robert
Brunner, Maximilian
author_sort Jacobsen, Anne
collection PubMed
description (1) Background: Delay in therapy for pancreatic ductal adenocarcinoma (PDAC) may contribute to a worse outcome. The aim of this study was to investigate the prognostic value of time from diagnosis to surgery in patients undergoing upfront surgery for primarily resectable pancreatic carcinoma. (2) Methods: This retrospective single-center study included 214 patients who underwent primary resection of PDAC from January 2000 to December 2018 at University Hospital Erlangen. Using a minimum p-value approach, patients were stratified according to time to surgery (TtS) into two groups: TtS ≤ 23 days and TtS > 23 days. Postoperative outcome and long-term survival were compared. (3) Results: Median TtS was 25 days. The best cut-off for TtS was determined as 23 days. There were no differences regarding postoperative outcome or overall survival (OS) and disease-free survival (DFS) (OS: 23.8 vs. 20.4 months, p = 0.210, respectively, and DFS: 15.8 vs. 13.6 months, p = 0.187). Multivariate analysis revealed age, lymph node metastasis, tumor differentiation and resection status as significant independent prognostic predictors for OS and DFS. (4) Conclusions: A delay of surgery > 23 days after first diagnosis does not affect overall or disease-free survival of patients with primary resectable PDAC. However, the psychological impact of a delay to patients waiting for surgery should not be underestimated.
format Online
Article
Text
id pubmed-9369379
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93693792022-08-12 Time to Surgery Does Not Affect Overall or Disease-Free Survival of Patients with Primary Resectable PDAC Jacobsen, Anne Hobbs, Mirianna Merkel, Susanne Mittelstädt, Anke Czubayko, Franziska Krautz, Christian Weber, Georg F. Grützmann, Robert Brunner, Maximilian J Clin Med Article (1) Background: Delay in therapy for pancreatic ductal adenocarcinoma (PDAC) may contribute to a worse outcome. The aim of this study was to investigate the prognostic value of time from diagnosis to surgery in patients undergoing upfront surgery for primarily resectable pancreatic carcinoma. (2) Methods: This retrospective single-center study included 214 patients who underwent primary resection of PDAC from January 2000 to December 2018 at University Hospital Erlangen. Using a minimum p-value approach, patients were stratified according to time to surgery (TtS) into two groups: TtS ≤ 23 days and TtS > 23 days. Postoperative outcome and long-term survival were compared. (3) Results: Median TtS was 25 days. The best cut-off for TtS was determined as 23 days. There were no differences regarding postoperative outcome or overall survival (OS) and disease-free survival (DFS) (OS: 23.8 vs. 20.4 months, p = 0.210, respectively, and DFS: 15.8 vs. 13.6 months, p = 0.187). Multivariate analysis revealed age, lymph node metastasis, tumor differentiation and resection status as significant independent prognostic predictors for OS and DFS. (4) Conclusions: A delay of surgery > 23 days after first diagnosis does not affect overall or disease-free survival of patients with primary resectable PDAC. However, the psychological impact of a delay to patients waiting for surgery should not be underestimated. MDPI 2022-07-29 /pmc/articles/PMC9369379/ /pubmed/35956049 http://dx.doi.org/10.3390/jcm11154433 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Jacobsen, Anne
Hobbs, Mirianna
Merkel, Susanne
Mittelstädt, Anke
Czubayko, Franziska
Krautz, Christian
Weber, Georg F.
Grützmann, Robert
Brunner, Maximilian
Time to Surgery Does Not Affect Overall or Disease-Free Survival of Patients with Primary Resectable PDAC
title Time to Surgery Does Not Affect Overall or Disease-Free Survival of Patients with Primary Resectable PDAC
title_full Time to Surgery Does Not Affect Overall or Disease-Free Survival of Patients with Primary Resectable PDAC
title_fullStr Time to Surgery Does Not Affect Overall or Disease-Free Survival of Patients with Primary Resectable PDAC
title_full_unstemmed Time to Surgery Does Not Affect Overall or Disease-Free Survival of Patients with Primary Resectable PDAC
title_short Time to Surgery Does Not Affect Overall or Disease-Free Survival of Patients with Primary Resectable PDAC
title_sort time to surgery does not affect overall or disease-free survival of patients with primary resectable pdac
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9369379/
https://www.ncbi.nlm.nih.gov/pubmed/35956049
http://dx.doi.org/10.3390/jcm11154433
work_keys_str_mv AT jacobsenanne timetosurgerydoesnotaffectoverallordiseasefreesurvivalofpatientswithprimaryresectablepdac
AT hobbsmirianna timetosurgerydoesnotaffectoverallordiseasefreesurvivalofpatientswithprimaryresectablepdac
AT merkelsusanne timetosurgerydoesnotaffectoverallordiseasefreesurvivalofpatientswithprimaryresectablepdac
AT mittelstadtanke timetosurgerydoesnotaffectoverallordiseasefreesurvivalofpatientswithprimaryresectablepdac
AT czubaykofranziska timetosurgerydoesnotaffectoverallordiseasefreesurvivalofpatientswithprimaryresectablepdac
AT krautzchristian timetosurgerydoesnotaffectoverallordiseasefreesurvivalofpatientswithprimaryresectablepdac
AT webergeorgf timetosurgerydoesnotaffectoverallordiseasefreesurvivalofpatientswithprimaryresectablepdac
AT grutzmannrobert timetosurgerydoesnotaffectoverallordiseasefreesurvivalofpatientswithprimaryresectablepdac
AT brunnermaximilian timetosurgerydoesnotaffectoverallordiseasefreesurvivalofpatientswithprimaryresectablepdac